SGHT Sight Sciences, Inc.
USHealthcareAs of 2026-07-10 16:00
Why SGHT matters now
Sight Sciences, Inc. (SGHT) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.32 with +1.14% on the session and $289.5M in market capitalization; recent performance reads 1-month +11.86% and YTD -33.42%.
The latest financial table shown here is Q1 2026, with revenue of $19.7M, net income of $-13.0M, and EPS of $-0.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -8.8%.
The latest indexable market news headline is "Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.00; recent insider activity includes Encrantz Staffan filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.28
P/S
3.61
EV/EBITDA
-7.70
DCF Value
$1.76
FCF Yield
-8.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.2%
Operating Margin
-44.8%
Net Margin
-46.8%
ROE
-59.1%
ROA
-34.0%
ROIC
-37.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $19.7M | $-13.0M | $-0.24 |
| Q4 2025 | $20.4M | $-4.2M | $-0.08 |
| FY 2025 | $77.4M | $-38.4M | $-0.74 |
| Q3 2025 | $19.9M | $-8.2M | $-0.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.50
Target (Median)
$9.00
Target Range
$8.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
2.40
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.